New report with sales data for recombinant therapeutic antibodies and proteins shows continued success of innovative antibodies
- Category: Antibodies
- Published on Monday, 09 March 2020 14:16
- Hits: 1539
BARCELONA, Spain I March 9, 2020 I La Merie Publishing just released the 14th edition of it annual reports about sales of Blockbuster Biologics. The report Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2019.
Global sales of branded originator biologics increased by 10.9% to US$ 224 bln compared with the previous year. A total of 55 biologic therapeutics reached blockbuster status with 2019 sales exceeding US$ 1 bln: 36 antibodies and 19 proteins. Antibody sales represented more than 70% of total biologics sales in 2019. Eleven biologics reached global sales in 2019 of more than US$ 5 bln. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.
Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2019 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2019. In addition, sales data for major biosimilar antibodies and proteins are presented
Analysis of sales data for individual products and product classes show the impact of biosimilars on sales originator products as well as the success of defense strategies. The data also show which new product classes are contributing to the continued growth of biologics sales.
Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 4, 2020. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).
The report Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/blockbuster-biologics-2019-sales-of-recombinant-therapeutic-antibodies-proteins/
For those interested in historic sales data of biologics, La Merie Publishing offers a subscription to its online Sales Database for Therapeutic Antibodies & Proteins: 1-Year Subscription at https://lamerie.com/report/sales-database-for-therapeutic-antibodies-proteins-1-year-subscription/ . Subscription to the database includes a pdf copy of the new report about 2019 Biologics Sales.
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports as well as competitor analysis reports and target pipeline lists, the latter two in a tabulated format with structured listings of industry-relevant data. La Merie Publishing products can be purchased the online store www.lamerie.com and at selected Resellers.
The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. La Merie pays special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.
To leverage its expertise and knowledge accumulated in the in-house database, La Merie Publishing offers custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing